PHILADELPHIA, June 19, 2017 /PRNewswire/ -- Hyalo Technologies today announced the appointment of Bob Oliver as a member of the Board of Directors and Chief Executive Adviser.
"We are pleased to welcome Bob to the Hyalo Technologies leadership team. Bob brings more than 25 years of progressive leadership experience and a strong track record of driving top tier performance. I am confident that Bob will provide immediate leadership and focus to a range of initiatives which will support our growth strategy," said Dr. Shalabh Jain, President & Chief Executive Officer of Hyalo Technologies. "We are pleased to welcome Bob to the Hyalo Technologies Board of Directors & as Chief Executive Adviser," said Dr. Jain. "Bob has a wealth of experience in the Pharmaceutical industry. His business acumen, combined with nearly two decades of global knowledge in this industry, will serve as a valuable asset to Hyalo Technologies as we continue our global growth. We are delighted to have such experienced industry professionals as part of our Board."
"I am delighted to have the opportunity to join a talented leadership team at Hyalo Technologies with their commitment to people, customers and growth," said Mr. Oliver.
Bob Oliver most recently served as President and CEO of Otsuka America Pharmaceutical, Inc., (OAPI). He was responsible for overseeing OAPI's diverse and growing product portfolio across the neuroscience, cardiovascular, oncology, and medical device markets. Bob drove the organization toward a vision that reached beyond innovative medicines to provide solutions, access, and education, encouraging employees to view their work as fighting disease, confronting stigma, and resisting the status quo. Prior to joining Otsuka, Bob was Vice President and Global Business Manager for Oncology at Wyeth. Bob also gave leadership to the Vaccines Division and Primary Care at Wyeth while eventually assuming responsibility for U.S. Commercial Operations including Puerto Rico and the Caribbean. Bob began his career in pharmaceuticals with Johnson & Johnson, holding positions of increasing responsibility in sales, marketing, business operations and corporate management.
Bob earned a bachelor's degree from Rutgers University and an M.B.A. degree in Marketing from the Haub School of Business at Saint Joseph's University, where he now sits on the Pharma Board of Advisors. Bob also serves as a member of the Board for Academic Fellows at Eastern University, where he mentors doctoral candidates. Bob serves as Board Chairman for Otsuka Canada Pharmaceuticals, Inc.
About Hyalo Technologies
Hyalo Technologies is a Biotech & Pharmaceutical company establishing the next generation of drug delivery with the aim to develop a product to help clinicians address limited drug delivery options that are available to administer to patients. The company strives to leverage technology and research to effectively enhance efficacy and therapeutic effect.
Through its innovative nanotechnology drug delivery system, Hyalo Technologies will be able to drastically reduce systemic side effects and increase patient compliance. This is accomplished through a revolutionary drug delivery system that offers Target-Specific drug delivery, Time-Controlled drug release, Sequential Drug Delivery Intelligence, and 100% biodegradability.
Hyalo Technologies is open to collaborations such as Joint Ventures with established biotech and pharmaceutical companies to produce and market our products globally. Our Vision is to design and develop innovative healthcare products, which are of the highest caliber, quality and safety. Hyalo Technologies R&D labs and corporate offices are based in Philadelphia, Pennsylvania USA.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bob-oliver-brings-extensive-experience-to-guide-hyalo-technologies-companys-growth-300475911.html
SOURCE Hyalo Technologies